|
Jan 9
|
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
|
|
Jan 9
|
Stocks to Watch Tuesday: Boeing, Match, HPE, JetBlue
|
|
Dec 27
|
Novartis (NVS) Outperforms Broader Market: What You Need to Know
|
|
Dec 26
|
The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours
|
|
Dec 20
|
Novartis (NVS) Stock Moves -1.17%: What You Should Know
|
|
Dec 20
|
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
|
|
Dec 19
|
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
|
|
Dec 11
|
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Dec 10
|
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
|
|
Dec 8
|
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
|
|
Dec 8
|
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
|
|
Dec 7
|
Radiopharma startup Artbio raises $90M in sign of field’s momentum
|
|
Dec 6
|
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
|
|
Dec 6
|
Novartis gets FDA approval of closely watched rare disease drug
|
|
Dec 6
|
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
|
|
Dec 5
|
UPDATE 3-Merck KGaA suffers major blow as MS drug fails in late-stage trials
|
|
Dec 4
|
UPDATE 1-Blackstone explores sale of Anthos Therapeutics -sources
|
|
Dec 4
|
Blackstone explores sale of Anthos Therapeutics -sources
|
|
Dec 1
|
Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More
|
|
Nov 30
|
25 Most Expensive Countries in the World to Raise a Child
|